InteliCare Holdings Limited

InteliCare Holdings Limited

AASX:ICR
0.02
AUD
0.00
(0.00%)
0.00EPS
2.92MMarket Cap
Mar 04Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.01
0.01
- -
- -
- -
- -
Basic EPS, GAAP
-0.05
-0.08
-0.03
-0.02
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
0.05
0.05
0.01
- -
- -
- -
Tangible Book Value per Share
0.05
0.05
0.01
- -
- -
- -
Basic Weighted Avg Shares
49
54
115
166
225
455
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
Operating Margin (%)
-972.37
-1,354.05
-1,103.56
-1,008.58
-1,108.7
-291.34
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
-4
-4
-3
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-954.68
-1,200.93
-914.97
-741.49
-806.06
-234.57
Working Capital
4
2
1
1
- -
-1
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
4
3
2
1
- -
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-131.92
-190.35
-240.52
- -
- -

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
32.54%
394.99%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
2.37%
-0.67%
Sales/Revenue/Turnover
- -
51.77%
241.34%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
1

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.02
2024
- -
- -
-0.01
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Angus Cameron
Full Time Employees
8
Sector
Electronic technology
Industry
Computer peripherals
Address
299 Vincent Street Leederville WA Australia 6007
IPO Date
May 29, 2020
Business
Intelicare Holdings Limited (ASX:ICR) develops and commercializes predictive analytics hardware and software platforms for the aged care, disability, and healthcare sectors in Australia. Founded in 2016 and headquartered at Level 1, 299 Vincent Street, Leederville, Western Australia, the company offers a smart home platform integrating artificial intelligence to monitor activity levels, behavior patterns, health metrics, sleep, and other indicators for caregivers, enabling early detection and prevention of incidents, emergencies, and health declines; hardware solutions including smart home sensors, a two-way voice hub for instant emergency alerts and duress call triage, emergency detection devices such as pendants and panic buttons, and vitals monitoring devices; a 24/7 live data access platform with alerts and daily summaries for unlimited users; downloadable applications; and optional duress pendants, with substantial revenue derived from hardware sales. The company targets care providers, families, and independent living residents in residential aged care facilities, group homes, retirement villages, and supported independent living environments, primarily operating within Australia. Recent developments include a February 2024 subscription agreement with Hardi Aged Care for deployment across all six of its residential facilities, marking the largest commercial rollout to date with implementation payments commencing in June 2024; a non-binding November 2023 memorandum of understanding with Bolton Clarke, Australia's largest independent not-for-profit aged care provider, leading to trials; a May 2024 memorandum of understanding with Vlepis Solutions for platform integration with remote monitoring devices, paving the way for a strategic reseller agreement; capital raisings totaling $2.6 million through a $600,000 placement in December 2023 and a $2 million two-tranche placement in June 2024; and conclusion of a pilot study with Peter MacCallum Cancer Centre in early 2024, with plans for a second phase in fiscal year 2025 alongside discussions with other healthcare providers.